Tuesday, 23 Apr 2019

You are here

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

Investigators analyzed and compared 570 patients treated with etanercept (ETN), infliximab (INF) or adalimumab (ADL). Compared with SpA (n = 294) patients, RA patients (n = 276) were more likely to be female (80 vs 39%), older (56 vs 48 years), on DMARDs (83 vs 47%) and had slightly longer disease control for longer (202 vs 170 weeks) before their secondary TNFi failure.

No anti-drug antibodies were found with ETN, but were seen INF (27.1%) and ADA (29.0%) treated patients; 81% of these had no detectable serum drug levels.

While significiantly more SpA (31.3%) patients had anti-INF antibodies than RA (21.1%; P = 0.014), there were few patients patients developing anti-drug antibodies while on concomitant DMARDs (16.5%) compared to those on on monotherapy (26.4%; P < 0.05).

While these data show the potential impact of anti-drug antibodies in the loss of TNFi, efficacy, it appears to be a minor role (<30% of patients) and is not otherwise explained by concomitant DMARD use or the disorder under treatment.  Secondarly anti-TNF failure appears to have multiple etiologies.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

How to order for drug antibodies for those of us in community practice?

More Like This

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).

Biomarker Combo Predicts TNF Inhibitor Responses

Based on clinical trial data, patients starting tumour necrosis factor-alpha inhibitors (TNFi) have roughly a two-thirds chance of achieiving a good clinical response. French investigators have studied a series of potential biomarkers and surmised that the combination of baseline prealbumin, platelet factor 4 and S100A12 can predict a 78% response to TNFi in rheumatoid arthritis (RA) patients.